Use of Metastatic Gene Signatures in the Diagnosis, Prognosis, and Treatment of Metastasis and Tumor Self-Seeding
SK1182/SK1270/SK1351/SK1375
This portfolio describes the use of metastatic gene signatures as a tool for the diagnosis, prognosis, and treatment of metastases and tumor self-seeding. Included is a method to determine the metastatic and self-seeding potential of a variety of cancers as well as screen for potential compounds that block metastasis and/or self-seeding (SK1270). The unique gene signatures which drive breast cancer metastasis to the lung and brain (SK1182/SK1351/SK1375) were identified using the methods described in SK1270. The ability to determine the unique gene signatures of metastatic cancer cells allows identification of critical regulators of metastasis and potential new therapeutic targets.
Joan Massagué, PhD
Larry Norton, MD
| SKI Reference | Title | Peer-Reviewed Publication | Patent Status |
|---|---|---|---|
| SK1182 | Genes that mediate breast cancer metastasis to the lung | Nature (2005) Vol 436 Pg 518 | US Patent: 8,178,505 and US Div Application No: 13/447,684 |
| SK1270 | Assay for anti-metastatic agents | Nature (2005) Vol 436 Pg 518 | US Patent: 7,829,066 |
| SK1351 | Gene Signatures for the Prognosis of Breast Cancer | Cell (2008) Vol 133 Pg 66 | US Publication No: 2011/0053804 |
| SK1375 | Genes That Mediate Metastasis and Primary Tumor Growth | Nature (2009) Vol 459 Pg 1005 | US Publication No:2010/0029748 |
Lisa Placanica, PhD
Licensing Manager
Tel: 212-639-6181; Fax: 212-717-3439
E-mail: placanil@mskcc.org